ORTHOGEN LAB SERVICES GMBH

New, natural ways in joint disorders and sports injuries

Together with Klaus Wehling and the biologist Dr. Julio Reinecke, Professor Dr. med. Peter Wehling founded the company ORTHOGEN in 1993. This was inspired by his research for American universities, where the world-renowned osteoarthritis specialist was looking for a gentle, joint-preserving alternative to the traditional surgical methods. ORTHOGEN Lab Services GmbH is a subsidiary of ORTHOGEN AG. Since 2002, ORTHOGEN Lab Services GmbH has been globally distributing a patented medical device – the EOT®II syringe. This device is typically used by office-based physicians for preparing autologous conditioned serum (ACS). The ORTHOGEN Group conducts its research and development as well as its manufacturing in Germany. And in the future? The makers have big plans.

In addition to Professor Dr. med. Peter Wehling, Dr. rer. nat. Julio Reinecke (Head of Research and Development of ORTHOGEN AG), Dr. med. Tanju Kaptan (Medical Director of ORTHOGEN AG) and Dr. rer. nat. Hendrik Rönsch (Managing Director of ORTHOGEN Lab Services GmbH) are the masterminds of the ORTHOGEN-Gruppe.

Prof. Dr. med. Peter Wehling

Independent orthopaedist and co-inventor of the EOT®II therapy, as well as CEO of ORTHOGEN AG.

Dr. rer. nat. Julio Reinecke

Biologist, co-inventor and founder of ORTHOGEN AG. Head of the Research and Development Department of ORTHOGEN AG.

Dr. rer. nat. Hendrik Rönsch

Biotechnologist and Managing Director of ORTHOGEN Lab Services GmbH. Previously held senior positions at Biotronik und Bausch+Lomb Surgical.

Dr. med. Tanju Kaptan

Physician and Medical Director of ORTHOGEN AG. Previously held senior positions at pharmaceutical companies.


 Going new, gentle, joint-conserving ways: Step by step

  1. 1993: Establishment of ORTHOGEN AG in Düsseldorf with a focus on molecular orthopaedics
  2. 1996: Development of the ACS therapy (autologous conditioned serum)
  3. 2001: Market launch of the first ORTHOKIN® syringe
  4. 2002: Development of the Arthromatrix® autologous chondrocyte transplantation
  5. 2002: Establishment of ORTHOGEN Lab Services GmbH as distributor
  6. 2004: Development and launch of the EOT®II syringe to optimise the ACS therapy
  7. 2004: Publication of the muscle regeneration study with 29 patients
  8. 2007: Publication of the double-blind trial on 84 patients with nerve root compression
  9. 2009: Publication of the double-blind knee osteoarthritis study on 376 patients with the medical device EOT®II
  10. 2013: Internationalisation and expansion of the global business
  11. 2014: International ORTHOKIN® Symposium in Varazdin (Croatia)
  12. 2015: More than 400,000 medical devices sold worldwide
  13. 2015: Publication of the observational study over 2 years with 118 knee osteoarthosis patients.
  14. 2016: Publication of the the review “How does surgery compare with advanced intra-articular therapies in knee osteoarthritis: current thoughts”
  15. 2016: 10.-11.6.2016 1. International Symposium for Molekulare Medicine in Düsseldorf, organized from Stiftung Molekulare Medizin.